An open-label phase Ib study of ORIC-101 in combination with enzalutamide in patients with metastatic prostate cancer progressing on enzalutamide-MedSci.cn

An open-label phase Ib study of ORIC-101 in combination with enzalutamide in patients with metastatic prostate cancer progressing on enzalutamide

Shore, ND; Efstathiou, E; Patel, R; Xu, RD; Johnson, A; Multani, PS; Morris, MJ; Abida, W

JOURNAL OF CLINICAL ONCOLOGY, 2020; 38 (6):

科室
- - 订阅+
  - 更多科室
工具
服务